跳至主要内容
临床试验/CTRI/2024/06/068710
CTRI/2024/06/068710尚未招募2/3 期

To evaluate the impact of intravenous iron therapy in chronic kidney disease patients with heart failure A randomised controlled study

Shrinath Mashale1 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2024年6月20日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
128
试验地点
1
主要终点
2)New York Heart Association (NYHA) functional class

研究概览

简要总结

This thesis explores the multifaceted role of iron in the complex interplay between chronic kidney disease (CKD) and chronic heart failure (CHF) through a randomized controlled trial (RCT). The study examines the consequences of iron deficiency in these conditions and investigates the potential of iron correction as a therapeutic strategy.

Specifically, it compares the effectiveness of intravenous (IV) iron isomaltoside 1 gm in one arm versus oral iron in the other arm.

By highlighting the critical role of iron in managing iron deficiency in patients with CKD and CHF, this research aims to enhance our understanding of the Cardio Renal Iron Deficiency (CRID) syndrome and pave the way for improved treatment modalities in this challenging clinical scenario.

It also compares exercise capacity and eGFR, EF post 3 months of drug administration.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Age more than 18 years left ventricular ejection fraction less than 50% NYHA class 2-4 CKD with estimated glomerular filtration rate less than 60 ml/min/1.73m2 Iron deficiency serum iron less than 800ug/ml and transferrin saturation less than 30% No previous exposure to intravenous iron therapy within last 3 months.

排除标准

  • Haematological criteria serum ferritin more than 800ug/ml Transferrin saturation more than 30 % CKD patients on maintenance hemodialysis Already received IV iron contraindications to iron therapy.

结局指标

主要结局

2)New York Heart Association (NYHA) functional class

时间窗: 12 weeks

1)Exercise capacity measured by the six-minute walk test (6MWT)

时间窗: 12 weeks

3)eGFR

时间窗: 12 weeks

4)MACE

时间窗: 12 weeks

次要结局

  • •Hemoglobin concentration in CKD patients with anemia.(•Improvement in iron indices (e.g., serum ferritin, transferrin saturation))

研究者

发起方
Shrinath Mashale
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Shrinath Mashale

Post graduate institute of medical education and research

研究点 (1)

Loading locations...

相似试验